Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Jefferies Financial Group

Key Points

• Jefferies initiated coverage with a buy rating and a $19 price target, implying roughly 124.85% upsideModerate Buy with an average analyst target of $48.80 and mixed recent analyst moves.
• Shares trade around $8.45 with a market cap near $81 million and a 52‑week range of $6.01–$17.44; Adicet reported Q1 EPS of ($2.94), topping estimates, though analysts forecast a roughly -10.26 EPS for the year.
• Major shareholder Ra Capital bought 74,751 shares at $7.27, increasing its position; insiders acquired 223,596 shares last quarter (insiders own 4.6%) and institutional investors hold about 83.89% of the stock.

Equities research analysts at Jefferies Financial Group began coverage on shares of Adicet Bio (NASDAQ:ACET - Get Free Report) in a report issued on Tuesday. The brokerage set a "buy" rating and a $19.00 price target on the stock. Jefferies Financial Group's price objective indicates a potential upside of 124.85% from the company's previous close.

Other analysts have also recently issued reports about the company. HC Wainwright dropped their price target on Adicet Bio from $50.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, March 23rd. Weiss Ratings upgraded Adicet Bio from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, April 24th. Canaccord Genuity Group set a $18.00 target price on shares of Adicet Bio and gave the stock a "buy" rating in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of Adicet Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday. Finally, Truist Financial upgraded shares of Adicet Bio to a "strong-buy" rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Adicet Bio has a consensus rating of "Moderate Buy" and an average target price of $48.80.

Adicet Bio Stock Up 3.0%

Adicet Bio stock opened at $8.45 on Tuesday. The business's 50-day moving average price is $7.24 and its 200 day moving average price is $8.62. The firm has a market cap of $81.09 million, a price-to-earnings ratio of -0.47 and a beta of 1.50. Adicet Bio has a 52 week low of $6.01 and a 52 week high of $17.44.

Adicet Bio (NASDAQ:ACET - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($2.94) EPS for the quarter, topping analysts' consensus estimates of ($3.23) by $0.29. Equities analysts expect that Adicet Bio will post -10.26 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Ra Capital Management, L.P. bought 74,751 shares of the company's stock in a transaction dated Friday, February 20th. The shares were acquired at an average price of $7.27 per share, with a total value of $543,439.77. Following the completion of the acquisition, the insider owned 1,182,624 shares in the company, valued at approximately $8,597,676.48. This trade represents a 6.75% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 223,596 shares of company stock valued at $1,603,934 in the last quarter. Insiders own 4.60% of the company's stock.

Institutional Trading of Adicet Bio

Several hedge funds and other institutional investors have recently made changes to their positions in ACET. Susquehanna International Group LLP purchased a new position in Adicet Bio in the third quarter valued at about $33,000. Squarepoint Ops LLC purchased a new stake in shares of Adicet Bio during the 3rd quarter worth approximately $38,000. FNY Investment Advisers LLC purchased a new stake in shares of Adicet Bio during the 4th quarter worth approximately $51,000. Virtu Financial LLC acquired a new stake in shares of Adicet Bio in the 3rd quarter worth approximately $65,000. Finally, Maven Securities LTD acquired a new stake in shares of Adicet Bio in the 4th quarter worth approximately $263,000. Institutional investors and hedge funds own 83.89% of the company's stock.

About Adicet Bio

Adicet Bio, Inc NASDAQ: ACET is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company's proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet's lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.